{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:55:17Z","timestamp":1790744117793,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.farma.2026.08.009","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:57:54Z","timestamp":1790740674000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Art\u00edculo traducido] Regulaci\u00f3n de medicamentos hu\u00e9rfanos: una comparaci\u00f3n global de los enfoques de la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos, la Agencia Europea de Medicamentos y la Agencia Japonesa de Productos Farmac\u00e9uticos y Dispositivos M\u00e9dicos"],"prefix":"10.1016","author":[{"given":"Robinraja","family":"Elango","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivanand K.","family":"Mutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.farma.2026.08.009_bb0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4103\/0975-7406.72128","article-title":"Orphan drug: development trends and strategies","volume":"2","author":"Sharma","year":"2010","journal-title":"J Pharm Bioallied Sci [Internet]"},{"key":"10.1016\/j.farma.2026.08.009_bb0010","series-title":"Rare diseases at FDA [Internet]","author":"FDA","year":"2020"},{"key":"10.1016\/j.farma.2026.08.009_bb0015","author":"Committee for Orphan"},{"key":"10.1016\/j.farma.2026.08.009_bb0020","series-title":"Orphan drugs WG [Internet]","author":"PMDA","year":"2023"},{"issue":"12","key":"10.1016\/j.farma.2026.08.009_bb0025","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jval.2020.06.020","article-title":"Access and unmet needs of orphan drugs in 194 countries and 6 areas: a global policy review with content analysis","volume":"23","author":"Chan","year":"2020","journal-title":"Value Health [Internet]"},{"key":"10.1016\/j.farma.2026.08.009_bb0030","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.2147\/RMHP.S260641","article-title":"Ethical questions linked to rare diseases and orphan drugs \u2013 a systematic review","volume":"13","author":"Kacetl","year":"2020","journal-title":"Risk Manag Health Policy [Internet]"},{"issue":"10","key":"10.1016\/j.farma.2026.08.009_bb0035","doi-asserted-by":"crossref","first-page":"103755","DOI":"10.1016\/j.drudis.2023.103755","article-title":"Increasing orphan drug loss in Japan: Trends and R&D strategy for rare diseases","volume":"28","author":"Enya","year":"2023","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.farma.2026.08.009_bb0040","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/healthcare11040558","article-title":"Disentangling the cost of orphan drugs marketed in the United States","volume":"11","author":"Althobaiti","year":"2023","journal-title":"Healthcare"},{"issue":"1","key":"10.1016\/j.farma.2026.08.009_bb0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1377\/hlthaff.2023.00219","article-title":"Orphan drug label expansions: analysis of subsequent rare and common indication approvals","volume":"43","author":"Miller","year":"2024","journal-title":"Health Aff (Project Hope)"},{"issue":"1","key":"10.1016\/j.farma.2026.08.009_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13023-023-02790-7","article-title":"A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the orphan drug act","volume":"18","author":"Fermaglich","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.farma.2026.08.009_bb0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1377\/hlthaff.2020.01442","article-title":"Spending for orphan indications among top-selling orphan drugs approved to treat common diseases","volume":"40","author":"Chua","year":"2021","journal-title":"Health Aff"},{"issue":"1","key":"10.1016\/j.farma.2026.08.009_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-01901-6","article-title":"Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: Substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases","volume":"16","author":"Miller","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"10.1016\/j.farma.2026.08.009_bb0065","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40273-020-00934-2","article-title":"Market exclusivity for drugs with multiple orphan approvals (1983\u20132017) and associated budget impact in the US","volume":"38","author":"Padula","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.farma.2026.08.009_bb0070","doi-asserted-by":"crossref","first-page":"117170","DOI":"10.1016\/j.bmc.2023.117170","article-title":"Analysis of orphan designation status for FDA approved drugs, and case studies in oncology, neuroscience and metabolic diseases","volume":"80","author":"Brown","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.farma.2026.08.009_bb0075","series-title":"Designating an orphan product: drugs and biological products [Internet]","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.farma.2026.08.009_bb0080","article-title":"Orphan drugs: understanding the FDA approval process [Internet]","author":"Srivastava","year":"2019","journal-title":"Acad Entrep Med Health Sci"},{"key":"10.1016\/j.farma.2026.08.009_bb0085","series-title":"The European journal of health economics: HEPAC: health economics in prevention and care [Internet]","article-title":"Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy","volume":"25","author":"Michaeli","year":"2023"},{"key":"10.1016\/j.farma.2026.08.009_bb0090","series-title":"Expedited program for serious conditions [Internet]","author":"Center for drug evaluation and research","year":"2024"},{"key":"10.1016\/j.farma.2026.08.009_bb0095","series-title":"Accelerated approval confirmatory underway [Internet]","author":"Oncology center of excellence","year":"2025"},{"key":"10.1016\/j.farma.2026.08.009_bb0100","author":"Sosa"},{"issue":"12","key":"10.1016\/j.farma.2026.08.009_bb0105","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1016\/j.ymthe.2023.09.020","article-title":"The european landscape for gene therapies in orphan diseases: 6-year experience with the EMA committee for orphan medicinal products","volume":"31","author":"Palomo","year":"2023","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.farma.2026.08.009_bb0110","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/cpt.3397","article-title":"Assessing post-marketing requirements for orphan drugs: A cross-sectional analysis of FDA and EMA oversight","volume":"116","author":"Yu","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"7\u20138","key":"10.1016\/j.farma.2026.08.009_bb0115","first-page":"366","article-title":"Advancing rare disease treatment: EMA\u2019S decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation","volume":"31","author":"Magrelli","year":"2024","journal-title":"Gene Ther"},{"key":"10.1016\/j.farma.2026.08.009_bb0120","article-title":"EU pharma legislation review series: orphan medicines [Internet]. Inside EU","author":"Bogaert","year":"2023","journal-title":"Life Sci"},{"issue":"7","key":"10.1016\/j.farma.2026.08.009_bb0125","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MLR.0000000000001840","article-title":"Analysis of the gene therapies authorized by the United States Food and Drug Administration and the European Medicines Agency","volume":"61","author":"Ghanem","year":"2023","journal-title":"Med Care"},{"issue":"5","key":"10.1016\/j.farma.2026.08.009_bb0130","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.clinthera.2020.03.006","article-title":"Use of real-world data for new drug applications and line extensions","volume":"42","author":"Bolislis","year":"2020","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.farma.2026.08.009_bb0135","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2462","article-title":"Use of real-world data and evidence in drug development of medicinal products centrally authorized in europe in 2018\u20132019","volume":"111","author":"Eskola","year":"2021","journal-title":"Clin Pharmacol Therap"},{"issue":"1","key":"10.1016\/j.farma.2026.08.009_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-018-0926-z","article-title":"Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties","volume":"13","author":"Pontes","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.farma.2026.08.009_bb0145","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/j.clinthera.2015.05.378","article-title":"Milestones on orphan medicinal products development: the 100 first drugs for rare diseases approved throughout Europe","volume":"37","author":"Pontes","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.farma.2026.08.009_bb0155","author":"EMA"},{"key":"10.1016\/j.farma.2026.08.009_bb0160","author":"EMA"},{"key":"10.1016\/j.farma.2026.08.009_bb0165","author":"EMA"},{"issue":"1","key":"10.1016\/j.farma.2026.08.009_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-023-02685-7","article-title":"Orphan medical devices have come a long way","volume":"18","author":"Dooms","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.farma.2026.08.009_bb0175","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1248\/bpb.b23-00107","article-title":"Strengthening the competitiveness of Japan\u2019s pharmaceutical industry: analysis of country differences in the origin of new drugs and japans highly productive firm","volume":"46","author":"Okuyama","year":"2023","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"10.1016\/j.farma.2026.08.009_bb0185","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cpt.2080","article-title":"Evolving landscape of new drug approval in Japan and lags from international birth dates: retrospective regulatory analysis","volume":"109","author":"Tanaka","year":"2020","journal-title":"Clin Pharmacol Therap"},{"key":"10.1016\/j.farma.2026.08.009_bb0180","series-title":"Tepotinib: first approval. 80","first-page":"829","author":"Markham","year":"2020"},{"key":"10.1016\/j.farma.2026.08.009_bb0190","series-title":"Regulatory approach to promote orphan drug development in Japan [Internet]","author":"Aoi","year":"2021"},{"key":"10.1016\/j.farma.2026.08.009_bb0195","author":"MHLW"},{"key":"10.1016\/j.farma.2026.08.009_bb0200","series-title":"Regulatory approach to promote orphan drug development in Japan [Internet]","author":"Aoi","year":"2023"},{"key":"10.1016\/j.farma.2026.08.009_bb0205","series-title":"R&D briefing 101: new drug approvals in six major authorities 2015\u20132024: trends in an evolving regulatory landscape","author":"Lara","year":"2025"},{"key":"10.1016\/j.farma.2026.08.009_bb0210","first-page":"11","article-title":"Clinical development and marketing application review times for novel orphan-designated drugs","author":"Demirci","year":"2024","journal-title":"Front Med"},{"issue":"19","key":"10.1016\/j.farma.2026.08.009_bb0215","article-title":"Comparison of US and EU prices for orphan drugs in the perspective of the considered US orphan drugs act modifications and discussed price-regulation mechanisms adjustments in US and European Union","volume":"19","author":"\u017belewski","year":"2022","journal-title":"Int J Environ Res Public Health [Internet]"},{"issue":"1","key":"10.1016\/j.farma.2026.08.009_bb0220","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-025-03634-2","article-title":"Debates over orphan drug pricing: a meta-narrative literature review","volume":"20","author":"Hanchard","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.farma.2026.08.009_bb0225","author":"U. S. Government Accountability Office"},{"key":"10.1016\/j.farma.2026.08.009_bb0230","article-title":"A competitive and innovation-led Europe starts with rare diseases [Internet]","author":"Cooper","year":"2025","journal-title":"Parl Mag"},{"key":"10.1016\/j.farma.2026.08.009_bb0235","author":"Kiyohara"},{"key":"10.1016\/j.farma.2026.08.009_bb0240","author":"Rare disease day"},{"key":"10.1016\/j.farma.2026.08.009_bb0245","author":"PharmaRegulatory.in"},{"issue":"1","key":"10.1016\/j.farma.2026.08.009_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13696998.2025.2577514","article-title":"Toward an ethical future for orphan drugs: balancing access, affordability, and innovation","volume":"28","author":"Alum","year":"2025","journal-title":"J Med Econ"},{"key":"10.1016\/j.farma.2026.08.009_bb0255","author":"Rogers"},{"key":"10.1016\/j.farma.2026.08.009_bb0260","series-title":"Table of surrogate endpoints [Internet]","author":"FDA","year":"2025"},{"key":"10.1016\/j.farma.2026.08.009_bb0265","author":"Post-approval safety monitoring requirements for orphan drugs \u2013 clinical research made simple [internet]. Clinicalstudies.in 2025"},{"key":"10.1016\/j.farma.2026.08.009_bb0270","author":"Toth"},{"key":"10.1016\/j.farma.2026.08.009_bb0275","series-title":"From orphan drugs to inclusive research: bridging global gaps in rare disease treatment. In Chirmule N., Ghalsasi V.V., eds. Approved: the life cycle of drug development. Switzerland: Springer","first-page":"p. 443","author":"Rajasimha","year":"2025"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326002096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326002096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:58:00Z","timestamp":1790740680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326002096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":54,"alternative-id":["S1130634326002096"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.08.009","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Art\u00edculo traducido] Regulaci\u00f3n de medicamentos hu\u00e9rfanos: una comparaci\u00f3n global de los enfoques de la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos, la Agencia Europea de Medicamentos y la Agencia Japonesa de Productos Farmac\u00e9uticos y Dispositivos M\u00e9dicos","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.04.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}